N2,N4,N4-trimethyl-N2-(4-piperidinyl)-2,4-pyrimidinediamine | 199667-73-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N2,N4,N4-trimethyl-N2-(4-piperidinyl)-2,4-pyrimidinediamine
• 英文别名: 2-N,4-N,4-N-trimethyl-2-N-piperidin-4-ylpyrimidine-2,4-diamine
• CAS: 199667-73-7
• 化学式: C₁₂H₂₁N₅
• 分子量: 235.332
• InChiKey: KPSKCEHLQQTCAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  44.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N2,N4,N4-trimethyl-N2-(4-piperidinyl)-2,4-pyrimidinediamine 、 4,4,-二(4-氟苯)氯丁烷 在 potassium iodide 作用下， 生成 N2-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-N2,N4,N4-trimethyl-2,4-pyrimidinediamine
  参考文献：
  名称：

  2,4-diaminopyrimidine derivates as dopamine D4 receptor antagonist

  摘要：

  本发明涉及以下结构的化合物##STR1##其N-氧化物形式，药用酸可接受盐和立体化学异构体形式，其中Alk是C.sub.1-6烷二基或C.sub.3-6烯二基；R.sup.1是氢或C.sub.1-4烷基；R.sup.2和R.sup.3各自独立地是氢，C.sub.1-6烷基或C.sub.3-7环烷基；或R.sup.2和R.sup.3也可以与它们连接的氮原子一起取，从而形成吡咯烷，哌啶或全氢吡噁烷环；R.sup.4是氢或卤素；Q是芳基，芳氧基，二(芳基)甲基或杂芳基；芳基是萘基或苯基，所述的萘基和苯基可以选择性地被取代；杂芳基是喹啉基，异喹啉基，吡啶基，噻吩基，吲哚基，2,3-二氢-1,4-苯并二氧杂环基，2,3-二氢-苯并呋喃基或苯并二氧杂环基；所述的杂芳基可以选择性地被取代：还涉及它们的制备方法，包含它们的组合物以及它们作为药物的用途；含有放射性同位素的式(I)化合物；标记多巴胺D.sub.4受体位点的过程；以及成像器官的过程。

  公开号：

  US06159982A1

文献信息

• 2,4-diaminopyrimidine derivatives
  申请人：Janssen Pharmaceutica N.V.

  公开号：US06395742B1

  公开（公告）日：2002-05-28

  The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein Alk is C1-6alkanediyl or C3-6alkenediyl; R1 is hydrogen or C1-4alkyl; R2 and R3 each independently are hydrogen, C1-6alkyl or C3-7cycloalkyl; or R2 and R3 may also be taken together with the nitrogen atom to which they are attached, thus forming a pyrrolidine, a piperidine or a perhydro azepine ring; R4 is hydrogen or halo; Q is aryl, aryloxy, di(aryl)methyl or heteroaryl; aryl is naphthyl or phenyl, said naphthyl and phenyl may optionally be substituted; and heteroaryl is quinolinyl, isoquinolinyl, pyridinyl, thienyl, indolyl, 2,3-dihydro-1,4-benzodioxinyl, 2,3-dihydro-benzofuranyl or benzodioxolanyl; said heteroaryls may optionally be substituted; it further relates to processes for their preparation, compositions comprising them as well as their use as a medicine; compounds of formula (I) containing a radioactive isotope; a process of marking dopamine D4 receptor sites; and a process for imaging an organ are disclosed.

  本发明涉及公式中的化合物的N-氧化物形式，其药学上可接受的酸盐和立体化学异构体形式，其中Alk是C1-6烷二基或C3-6烯二基; R1是氢或C1-4烷基; R2和R3各自独立地是氢，C1-6烷基或C3-7环烷基; 或R2和R3也可以与它们连接的氮原子一起被取代，从而形成吡咯烷，哌嗪或过氢杂环庚烷环; R4是氢或卤素; Q是芳基，芳氧基，二（芳基）甲基或杂芳基; 芳基是萘基或苯基，所述萘基和苯基可以选择性地被取代; 而杂芳基是喹啉基，异喹啉基，吡啶基，噻吩基，吲哚基，2,3-二氢-1,4-苯并二氧杂环基，2,3-二氢苯并呋喃基或苯并二氧杂环基; 所述杂芳基可以选择性地被取代; 它进一步涉及它们的制备过程，包含它们的组合物以及它们作为药物的用途; 公式（I）中含有放射性同位素的化合物; 标记多巴胺D4受体位点的过程; 以及成像器官的过程。
• 2,4-diaminopyrimidine derivates as dopamine D4 receptor antagonist
  申请人：Janssen Pharmaceutica N. V.

  公开号：US06159982A1

  公开（公告）日：2000-12-12

  The present invention concerns the compounds of formula ##STR1## the N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein Alk is C.sub.1-6 alkanediyl or C.sub.3-6 alkenediyl; R.sup.1 is hydrogen or C.sub.1-4 alkyl; R.sup.2 and R.sup.3 each independently are hydrogen, C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl; or R.sup.2 and R.sup.3 may also be taken together with the nitrogen atom to which they are attached, thus forming a pyrrolidine, a piperidine or a perhydro azepine ring; R.sup.4 is hydrogen or halo; Q is aryl, aryloxy, di(aryl)methyl or heteroaryl; aryl is naphthyl or phenyl, said naphthyl and phenyl may optionally be substituted; and heteroaryl is quinolinyl, isoquinolinyl, pyridinyl, thienyl, indolyl, 2,3-dihydro-1,4-benzodioxinyl, 2,3-dihydro-benzofuranyl or benzodioxolanyl; said heteroaryls may optionally be substituted: it further relates to processes for their preparation, compositions comprising them as well as their use as a medicine; compounds of formula (I) containing a radioactive isotope; a process of marking dopamine D.sub.4 receptor sites; and a process for imaging an organ are disclosed.

  本发明涉及以下结构的化合物##STR1##其N-氧化物形式，药用酸可接受盐和立体化学异构体形式，其中Alk是C.sub.1-6烷二基或C.sub.3-6烯二基；R.sup.1是氢或C.sub.1-4烷基；R.sup.2和R.sup.3各自独立地是氢，C.sub.1-6烷基或C.sub.3-7环烷基；或R.sup.2和R.sup.3也可以与它们连接的氮原子一起取，从而形成吡咯烷，哌啶或全氢吡噁烷环；R.sup.4是氢或卤素；Q是芳基，芳氧基，二(芳基)甲基或杂芳基；芳基是萘基或苯基，所述的萘基和苯基可以选择性地被取代；杂芳基是喹啉基，异喹啉基，吡啶基，噻吩基，吲哚基，2,3-二氢-1,4-苯并二氧杂环基，2,3-二氢-苯并呋喃基或苯并二氧杂环基；所述的杂芳基可以选择性地被取代：还涉及它们的制备方法，包含它们的组合物以及它们作为药物的用途；含有放射性同位素的式(I)化合物；标记多巴胺D.sub.4受体位点的过程；以及成像器官的过程。